4. (First Time Amended) The method according to claim 1, wherein the agent is selected from the group consisting of an anti-LFA-3 antibody homolog, and a soluble CD2 polypeptide.

A2

5. (First Time Amended) The method according to claim 1, wherein the agent is selected from the group consisting of anti-CD2 antibody homolog and soluble LFA-3 polypeptide.

7. (First Time Amended) The method according to claim 6, wherein said soluble LFA-3 polypeptide is LFA3TIP (SEQ ID NO:8).

8. (First Time Amended) The method according to claim 4, wherein the agent is an anti-LFA-3 antibody homolog.

9. (First Time Amended) The method according to claim 5, wherein the agent is an anti-CD2 antibody homolog.

A3

10. (First Time Amended) The method according to claim 8, wherein the agent is a monoclonal anti-LFA-3 antibody.

11. (First Time Amended) The method according to claim 9, wherein the agent is a monoclonal anti-CD2 antibody.

12. (First Time Amended) The method according to claim 10, wherein the agent is a monoclonal anti-LFA-3 antibody produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1B11), ATCC HB 10695 (7A6), and ATCC HB 10696 (8B8) or is monoclonal antibody TS2/9.

A4

14. (First Time Amended) The method according to claim 8, wherein the agent is a chimeric recombinant anti-LFA-3 antibody homolog.

15. (First Time Amended) The method according to claim 9, wherein the agent is a chimeric recombinant anti-CD2 antibody homolog.

16. (First Time Amended) The method according to claim 8, wherein the agent is a humanized recombinant anti-LFA-3 antibody homolog.

17. (First Time Amended) The method according to claim 9, wherein the agent is a humanized recombinant anti-CD2 antibody homolog.

18. (First Time Amended) The method according to claim 8, wherein the agent is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab') 2 fragment, an F(v) fragment and an intact immunoglobulin heavy chain of an anti-LFA-3 antibody homolog.

A4

19. (First Time Amended) The method according to claim 9, wherein the agent is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab') 2 fragment, an F(v) fragment and an intact immunoglobulin heavy chain of an anti-CD2 antibody homolog.

20. (First Time Amended) The method according to claim 5, wherein the agent is a soluble LFA-3 polypeptide.

21. (First Time Amended) The method according to claim 4, wherein the agent is a soluble CD2 polypeptide.

22. (First Time Amended) The method according to claim 20, wherein the agent is a soluble LFA-3 polypeptide selected from the group consisting of AA_1-AA_{92} of SEQ ID NO:2, AA_1-AA_{80} of SEQ ID NO:2, AA_{50}-AA_{65} of SEQ ID NO:2, and AA_{20}-AA_{80} of SEQ ID NO:2.

24. (First Time Amended) The method according to claim 1, wherein the agent is administered at a dose between about 0.001 and about 50 mg agent per kg body weight.

A5

25. (First Time Amended) The method according to claim 24, wherein the agent is administered at a dose between about 0.01 and about 10 mg agent per kg body weight.

26. (First Time Amended) The method according to claim 24, wherein the agent is administered at a dose between about 0.1 and about 4 mg agent per kg body weight.

31. (First Time Amended) The method according to claim 1, wherein the agent is administered intravenously, intramuscularly, subcutaneously, intra-articularly, intrathecally, periostally, intratumorally, intralesionally, perilesionally by infusion, orally, topically or by inhalation.

32. (First Time Amended) The method according to claim 31, wherein the agent is administered intramuscularly, intravenously or subcutaneously.

A6

33. (First Time Amended) The method according to claim 4, wherein the agent is linked to one or more members independently selected from the group consisting of anti-LFA-3 antibody homologs, soluble CD2 polypeptides, cytotoxic agents and pharmaceutical agents.

34. (First Time Amended) The method according to claim 5, wherein the agent is linked to one or more members independently selected from the group consisting of anti-CD2 antibody homologs, soluble LFA-3 polypeptides, cytotoxic agents and pharmaceutical agents.

35. (First Time Amended) The method according to claim 34, wherein the agent is a polypeptide consisting of a soluble LFA-3 polypeptide linked to an immunoglobulin hinge and heavy chain constant region or portions thereof.

A6

36. (First Time Amended) The method according to claim 35, wherein said polypeptide is LFA3TIP (SEQ ID NO:8).

38. (First Time Amended) A method of preventing or treating psoriasis comprising the step of administering to a mammal a composition comprising an agent which binds to LFA-3 or CD2 selected from the group consisting of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog, in combination with a therapy selected from the group consisting of PUVA, chemotherapy and UV light.

A7

A8

44. (First Time Amended) The method of claim 43, wherein said soluble LFA-3 polypeptide is LFA3TIP (SEQ ID NO:8).

Please add new claims 49-54:

-- 49. The method according to claim 38, wherein the agent is a soluble LFA-3 polypeptide selected from the group consisting of AA_1-AA_{92} of SEQ ID NO:2, AA_1-AA_{80} of SEQ ID NO:2, AA_{50}-AA_{65} of SEQ ID NO:2, and AA_{20}-AA_{80} of SEQ ID NO:2.

50. The method according to claim 38, wherein the mammal is a human.

A9

51. The method of claim 1, wherein the therapy is UV light therapy.

52. The method of claim 38, wherein the therapy is UV light therapy.

53. A method of preventing or treating psoriasis comprising the step of administering to a mammal a composition comprising a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin heavy chain region and all or part of a heavy chain constant region in combination UV light therapy.

A9

54. The method of claim 53, wherein said soluble LFA-3 polypeptide is LFA3TIP (SEQ ID NO:8). --